NEW YORK, Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension
Therapeutics, Inc. ("DMTX" or the "Company") (NASDAQ: DMTX) in connection with the proposed acquisition of the Company by
Ultragenyx Pharmaceutical Inc. ("RARE") (NASDAQ: RARE). On October 2, 2017, the Company
issued a press release announcing its acceptance of RARE's "superior proposal" and the signing of a definitive agreement under
which terms RARE will acquire all outstanding shares of DMTX in a transaction valued at approximately $151.00 million, offering DTMX shareholders $6.00 for each share they
own.
WeissLaw is investigating whether DMTX's Board acted to maximize shareholder value prior to entering into the agreement.
Notably, at least one analyst set a target price of $9.00 per share, or $3.00 above the offer price.
Further, according Emil D. Kakkis, RARE's President and CEO, "[t]he acquisition [] provides a unique opportunity to approach
treatment of more rare diseases and advance [RARE's] development as a next generation rare disease company." The deal will
grant RARE access to DTMX's technology platform which will expand RARE into new therapeutic modalities and capabilities, and
diversifies its clinical and preclinical pipeline.
Given these facts, WeissLaw is investigating whether DMTX's Board acted in the best interests of DMTX's public shareholders to
maximize shareholder value prior to entering into the agreement. If you own DMTX shares and would like more information
about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com .
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief
in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email
us at stockinfo@weisslawllp.com or fill out
the form on our website, http://www.weisslawllp.com/dimension-therapeutics-inc/
View original content:http://www.prnewswire.com/news-releases/weisslaw-llp-dimension-therapeutics-inc-acquisition-may-not-be-in-the-best-interests-of-dmtx-shareholders-300536453.html
SOURCE WeissLaw LLP